Medivir to participate at the Kempen Life Sciences Conference - Apr 20, 2021

STOCKHOLM, April 20, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on April 21.

The presentation will be available via Medivirs website; www.medivir.com.

More information about the event is available at the organizer's website: https://www.kempen.com/en/securities/events/life-sciences-conference

For additional information, please contact
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com

Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com


Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-to-participate-at-the-kempen-life-sciences-conference,c3328867

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/medivir-to-participate-at-the-kempen-life-sciences-conference-301272196.html

SOURCE Medivir


Company Codes: Bloomberg:MVIRB@SS, ISIN:SE0000273294, RICS:MVIRB.ST, Stockholm:MVIRB

Back to news